Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Condition(s):PsoriasisLast Updated:January 29, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):PsoriasisLast Updated:January 29, 2021Unknown status
Condition(s):Psoriasis; Psoriatic ArthritisLast Updated:August 16, 2023Recruiting
Condition(s):PsoriasisLast Updated:March 15, 2024Active, not recruiting
Condition(s):PsoriasisLast Updated:August 1, 2023Recruiting
Condition(s):Crohn’s DiseaseLast Updated:March 19, 2024Recruiting
Condition(s):Healthy VolunteersLast Updated:March 10, 2022Completed
Condition(s):Genital Psoriasis; Scalp PsoriasisLast Updated:March 7, 2024Recruiting
Condition(s):Plaque Psoriasis; Psoriatic Arthritis; Crohn Disease; Other Conditions for Which Risankizumab is an FDA-approved TreatmentLast Updated:March 6, 2024Recruiting
Condition(s):Healthy VolunteersLast Updated:March 31, 2022Completed
Condition(s):Palmoplantar Pustulosis (PPP)Last Updated:December 5, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.